WO2025003978 - DEVICE AND METHODS FOR ADMINISTERING A THERAPEUTIC COMPOSITION TO THE PHARYNGEAL MUSCLE

National phase entry:
Publication Number WO/2025/003978
Publication Date 02.01.2025
International Application No. PCT/IB2024/056310
International Filing Date 28.06.2024
Title **
[English] DEVICE AND METHODS FOR ADMINISTERING A THERAPEUTIC COMPOSITION TO THE PHARYNGEAL MUSCLE
[French] DISPOSITIF ET PROCÉDÉS D'ADMINISTRATION D'UNE COMPOSITION THÉRAPEUTIQUE AU MUSCLE PHARYNGÉ
Applicants **
BENITEC IP HOLDINGS INC.
Inventors
MUKADAM, Sophie
BANKS, Jerel
ST-GUILY, Jean Lacau
Priority Data
63/510,750   28.06.2023   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting4087
EPO Filing, Examination, Granting54768
Japan Filing, Examination, Granting3869
South Korea Filing, Examination, Granting5378
USA Filing, Examination, Granting17340
MasterCard Visa
Total: 85,442

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] The present disclosure relates to devices and methods for administration of a therapeutic composition to the pharyngeal muscle. In particular, the devices and methods of the disclosure may be used in treatment or prevention of dysphagia, including dysphagia associated with oculopharyngeal muscular dystrophy (OPMD) in individuals suffering therefrom or predisposed thereto. Additionally, the present disclosure relates to devices and methods used to deliver modified adeno-associated virus (AAV) delivery vectors comprising 'silence and replace' DNA constructs, including compositions comprising same.[French] La présente divulgation concerne des dispositifs et des procédés d'administration d'une composition thérapeutique au muscle pharyngé. En particulier, les dispositifs et les procédés de la divulgation peuvent être utilisés dans le traitement ou la prévention de la dysphagie, notamment la dysphagie associée à la dystrophie musculaire oculopharyngée (OPMD), chez des individus atteints de celle-ci ou prédisposés à celle-ci. De plus, la présente divulgation concerne des dispositifs et des procédés utilisés pour administrer des vecteurs d'administration de virus adéno-associé (AAV) modifiés comprenant des constructions d'ADN « silence et remplacement », notamment des compositions les comprenant.

Rejoining the server...